NUVL

Nuvalent Inc

Oct 17 • 04:00PM ET

92.52

+2.10 2.32 %

Healthcare • Biotechnology • USA • NASD

Peers: ARQT ABUS TIL ALLO BEAM IMTX KRYS RGNX DTIL

| Held by: VTI VB IWM XBI VBR VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-4.90	Insider Own	38.07%	Shs Outstand	66.58M	Perf Week	5.02%
Market Cap	6.67B	Forward P/E	-	EPS next Y	-5.42	Insider Trans	-1.42%	Shs Float	44.66M	Perf Month	14.28%
Enterprise Value	5.67B	PEG	-	EPS next Q	-1.36	Inst Own	73.40%	Short Float	11.85%	Perf Quarter	12.20%
Income	-343.34M	P/S	-	EPS this Y	-36.36%	Inst Trans	-0.11%	Short Ratio	11.98	Perf Half Y	29.15%
Sales	0.00M	P/B	7.09	EPS next Y	-1.17%	ROA	-40.02%	Short Interest	5.29M	Perf YTD	18.19%
Book/sh	13.05	P/C	6.63	EPS next 5Y	1.10%	ROE	-43.55%	52W High	105.13 -11.99%	Perf Year	-9.67%
Cash/sh	13.95	P/FCF	-	EPS past 3/5Y	-59.96% -74.22%	ROIC	-36.54%	52W Low	55.53 66.60%	Perf 3Y	359.84%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.73% 4.66%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-76.16%	Oper. Margin	-	ATR (14)	3.67	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.57	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	65.39	Recom	1.19
Dividend Gr. 3/5Y	- -	Current Ratio	13.57	EPS Q/Q	-56.77%	SMA20	9.13%	Beta	1.30	Target Price	117.53
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	15.26%	Rel Volume	0.80	Prev Close	90.42
Employees	142	LT Debt/Eq	0.00	Earnings	Aug 07 BMO	SMA200	19.44%	Avg Volume	441.70K	Price	92.52
IPO	Jul 29, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.49% -	Trades		Volume	351,635	Change	2.32%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Resumed	Stifel	Buy	$115
Oct-15-25	Initiated	Cantor Fitzgerald	Overweight	$135
Sep-04-25	Resumed	Guggenheim	Buy	$122
Sep-03-25	Initiated	Raymond James	Outperform	$105
Aug-19-25	Initiated	Piper Sandler	Overweight	$112
Mar-14-25	Upgrade	UBS	Neutral → Buy	$100
Dec-30-24	Initiated	H.C. Wainwright	Buy	$110
Oct-24-24	Initiated	UBS	Neutral	$100
Aug-29-24	Initiated	Barclays	Overweight	$100
Apr-17-24	Initiated	Jefferies	Buy	$97
Apr-01-24	Upgrade	Leerink Partners	Market Perform → Outperform	$69 → $110
Feb-28-24	Resumed	Guggenheim	Buy	$99
Feb-23-24	Initiated	Robert W. Baird	Outperform	$105
Sep-27-23	Initiated	Stifel	Buy	$65
Aug-08-23	Initiated	SVB Securities	Market Perform	$42
Jul-24-23	Initiated	Guggenheim	Buy	$56
Jan-18-23	Initiated	Wedbush	Outperform	$39
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28

Show Previous Ratings

Today 06:00AM	Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025 (PR Newswire)
Oct-13-25 12:53PM	Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Sep-24-25 06:30AM	Nuvalent to Participate in the UBS 2025 Virtual Oncology Day (PR Newswire)
Sep-07-25 04:45AM	Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 (PR Newswire)
Sep-02-25 01:34AM	Piper Sandler Initiates Nuvalent (NUVL) Amid Key Cancer Drug Catalysts (Insider Monkey)
06:30AM	Loading…
Aug-28-25 06:30AM	Nuvalent to Participate in the Cantor Global Healthcare Conference 2025 (PR Newswire)
Aug-13-25 01:06PM	Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium (PR Newswire)
Aug-07-25 06:30AM	Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results (PR Newswire) -6.56%
Jul-21-25 06:30AM	Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC (PR Newswire)
06:30AM	Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naive ALK-positive NSCLC (PR Newswire)
Jul-06-25 04:00AM	Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer (Insider Monkey)
Jun-25-25 10:20AM	Nuvalent price target raised to $140 from $125 at Leerink (TipRanks)
10:15AM	Nuvalent price target raised to $130 from $110 at H.C. Wainwright (TipRanks)
Jun-24-25 06:30AM	Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC (PR Newswire)
06:30AM	Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug (BioPharma Dive)
04:30PM	Loading…
Jun-23-25 04:30PM	Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib (PR Newswire)
Jun-18-25 04:30PM	Nuvalent Appoints Christy Oliger to Board of Directors (PR Newswire)
May-08-25 07:31AM	Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results (PR Newswire) +7.31%
Apr-29-25 01:09PM	Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor (PR Newswire)
Apr-23-25 08:48PM	Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
12:47PM	Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
10:28AM	Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting (PR Newswire)
Apr-08-25 04:00PM	Nuvalent: Cannot Make Sense Of The Valuation (Seeking Alpha) -8.29% +9.07%
Apr-01-25 08:25AM	Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now? (Insider Monkey)
06:30AM	Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum (PR Newswire)
Mar-25-25 05:24PM	Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 (PR Newswire)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Feb-28-25 06:30AM	Nuvalent to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-27-25 06:30AM	Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-11-25 01:47PM	Why Insiders Are Selling Nuvalent, Inc. (NUVL) Recently (Insider Monkey)
03:07PM	Loading…
Jan-20-25 03:07PM	Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelmans Long-Term Stock Picks? (Insider Monkey)
Jan-13-25 06:30AM	Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones (PR Newswire) -6.20%
Dec-30-24 09:43AM	American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls (The Fly)
Dec-19-24 06:30AM	Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-09-24 06:30AM	Nuvalent Appoints Grant Bogle to Board of Directors (PR Newswire)
Nov-26-24 06:52AM	Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-12-24 06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results (PR Newswire)
Sep-18-24 04:05PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock (PR Newswire)
Sep-16-24 10:23PM	Nuvalent Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +28.27% -6.61%
04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily)
11:18AM	Cancer Biotech Nuvalents Stock Jumps on Positive Data (Barrons.com)
07:00AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Sep-14-24 07:57PM	Nuvalent, Inc. (NUVL): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
05:29PM	Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
05:00AM	Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines (PR Newswire)
Sep-13-24 09:53AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 (PR Newswire) +7.06%
Sep-09-24 06:30AM	Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles (PR Newswire)
Aug-29-24 06:30AM	Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-08-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-23-24 04:52AM	Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment (Clinical Trials Arena)
Jul-22-24 06:30AM	Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor (PR Newswire)
Jul-16-24 06:30AM	Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 (PR Newswire)
Jul-11-24 06:30AM	Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer (PR Newswire)
Jun-24-24 06:00AM	3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally (InvestorPlace)
May-29-24 06:30AM	Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference (PR Newswire)
May-17-24 04:48PM	Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing (MT Newswires)
06:31AM	FDA grants breakthrough therapy status for Nuvalents NVL-655 (Pharmaceutical Technology)
May-16-24 04:23PM	Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate (MT Newswires)
04:01PM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 (PR Newswire)
May-09-24 01:56PM	NUVL Stock Earnings: Nuvalent Misses EPS for Q1 2024 (InvestorPlace)
09:27AM	Nuvalent Q1 Loss Widens (RTT News)
07:19AM	Nuvalent Q1 Net Loss Widens (MT Newswires)
06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results (PR Newswire)
May-08-24 05:22PM	Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing (MT Newswires)
10:21AM	Why Earnings Season Could Be Great for Nuvalent (NUVL) (Zacks)
May-01-24 05:05PM	Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing (MT Newswires)
Apr-08-24 04:30PM	Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Apr-05-24 07:00PM	Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-29-24 07:01PM	Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-25-24 07:01PM	Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-19-24 07:01PM	Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-05-24 04:52PM	Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Feb-29-24 04:32AM	Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ... (GuruFocus.com)
Feb-27-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
06:15AM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 (PR Newswire)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-12-24 06:30AM	Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors (PR Newswire)
Feb-01-24 06:30AM	Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (PR Newswire)
Jan-08-24 06:30AM	Nuvalent Announces 'OnTarget 2026' Operating Plan and Key Anticipated Milestones (PR Newswire)
Dec-22-23 03:01PM	Director Anna Protopapas Sells 5,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Dec-21-23 01:01PM	Chief Development Officer Darlene Noci Sells 40,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30AM	Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-14-23 07:15PM	Nuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline Progress (GuruFocus.com)
06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-04-23 07:02AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Nov-01-23 06:30AM	Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 06:27PM	Why Nuvalent Stock Tanked on Tuesday (Motley Fool) -8.28%
Oct-16-23 09:55PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire)
07:30AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Oct-13-23 06:30AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC (PR Newswire)
Oct-07-23 01:00AM	Insider Sell: Chief Medical Officer Christopher Turner Sells 7,995 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Oct-05-23 07:13PM	Why Nuvalent Stock Skyrocketed 35% This Week (Motley Fool) +8.52%
10:29AM	Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data (Zacks)
01:01AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Oct-04-23 04:13PM	Why Nuvalent Stock Was Soaring Wednesday (Motley Fool) +35.57%
12:21PM	Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile (PR Newswire)
Sep-18-23 06:30AM	Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium (PR Newswire) -6.08%
Sep-05-23 06:30AM	Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors (PR Newswire)

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Porter James Richard	President and CEO	Oct 16 '25	Option Exercise	18.93	27,000	511,110	276,062	Oct 17 04:32 PM
Porter James Richard	President and CEO	Oct 16 '25	Sale	90.63	27,000	2,447,021	249,062	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 15 '25	Option Exercise	6.89	15,624	107,649	64,710	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 16 '25	Option Exercise	6.89	12,376	85,271	61,462	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 15 '25	Sale	89.98	15,624	1,405,848	49,086	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 16 '25	Sale	91.66	12,376	1,134,442	49,086	Oct 17 04:32 PM
Pelish Henry E.	Chief Scientific Officer	Oct 15 '25	Option Exercise	35.08	14,205	498,260	80,168	Oct 17 04:31 PM
Pelish Henry E.	Chief Scientific Officer	Oct 15 '25	Sale	90.04	14,205	1,279,018	65,963	Oct 17 04:31 PM
Balcom Alexandra	Chief Financial Officer	Oct 15 '25	Option Exercise	18.93	1,683	31,859	63,417	Oct 17 04:31 PM
Balcom Alexandra	Chief Financial Officer	Oct 15 '25	Sale	85.57	1,683	144,014	61,734	Oct 17 04:31 PM
James Richard Porter	Officer	Oct 16 '25	Proposed Sale	90.01	27,000	2,430,270		Oct 16 04:02 PM
DEBORAH MILLER	Officer	Oct 15 '25	Proposed Sale	84.66	54,000	4,571,640		Oct 15 04:37 PM
Balcom Alexandra	Chief Financial Officer	Oct 14 '25	Option Exercise	18.93	20,000	378,600	81,734	Oct 15 04:30 PM
Balcom Alexandra	Chief Financial Officer	Oct 13 '25	Option Exercise	14.79	20,000	295,825	81,734	Oct 15 04:30 PM
Balcom Alexandra	Chief Financial Officer	Oct 13 '25	Sale	88.51	20,000	1,770,288	61,734	Oct 15 04:30 PM
Balcom Alexandra	Chief Financial Officer	Oct 14 '25	Sale	86.20	20,000	1,724,016	61,734	Oct 15 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Oct 13 '25	Option Exercise	36.39	7,637	277,903	73,600	Oct 15 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Oct 14 '25	Option Exercise	25.67	2,433	62,460	68,396	Oct 15 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Oct 13 '25	Sale	89.81	7,637	685,879	65,963	Oct 15 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Oct 14 '25	Sale	85.78	2,433	208,699	65,963	Oct 15 04:30 PM
Alexandra Balcom	Officer	Oct 13 '25	Proposed Sale	89.32	48,558	4,337,206		Oct 14 04:08 PM
HENRY E PELISH	Officer	Oct 13 '25	Proposed Sale	88.10	21,842	1,924,280		Oct 14 07:43 AM
Balcom Alexandra	Chief Financial Officer	Oct 01 '25	Option Exercise	8.82	20,000	176,485	81,734	Oct 03 04:28 PM
Balcom Alexandra	Chief Financial Officer	Oct 01 '25	Sale	85.48	20,000	1,709,512	61,734	Oct 03 04:28 PM
Balcom Alexandra	Chief Financial Officer	Sep 30 '25	Option Exercise	6.89	20,000	137,800	81,734	Oct 01 08:17 PM
Balcom Alexandra	Chief Financial Officer	Sep 29 '25	Option Exercise	6.89	7,588	52,281	69,322	Oct 01 08:17 PM
Balcom Alexandra	Chief Financial Officer	Sep 30 '25	Sale	85.06	20,000	1,701,200	61,734	Oct 01 08:17 PM
Balcom Alexandra	Chief Financial Officer	Sep 29 '25	Sale	85.01	7,588	645,056	61,734	Oct 01 08:17 PM
Noci Darlene	Chief Development Officer	Sep 29 '25	Option Exercise	27.85	4,000	111,400	52,034	Oct 01 08:14 PM
Noci Darlene	Chief Development Officer	Sep 29 '25	Sale	83.07	4,000	332,288	48,034	Oct 01 08:14 PM
Darlene Noci	Officer	Sep 29 '25	Proposed Sale	81.30	12,000	975,600		Sep 29 04:08 PM
Alexandra Balcom	Officer	Sep 29 '25	Proposed Sale	81.30	60,000	4,878,000		Sep 29 04:07 PM
Porter James Richard	President and CEO	Sep 15 '25	Option Exercise	18.93	27,000	511,110	276,062	Sep 17 04:31 PM
Porter James Richard	President and CEO	Sep 15 '25	Sale	79.08	27,000	2,135,055	249,062	Sep 17 04:31 PM
Pelish Henry E.	Chief Scientific Officer	Sep 10 '25	Option Exercise	26.94	3,725	100,354	69,688	Sep 12 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Sep 10 '25	Sale	78.83	3,725	293,642	65,963	Sep 12 04:30 PM
HENRY E PELISH	Officer	Sep 10 '25	Proposed Sale	78.73	6,158	484,819		Sep 10 04:38 PM
Pelish Henry E.	Chief Scientific Officer	Aug 29 '25	Option Exercise	1.00	5,007	4,986	65,963	Sep 03 04:30 PM
Noci Darlene	Chief Development Officer	Aug 25 '25	Option Exercise	27.85	4,000	111,400	52,034	Aug 27 04:30 PM
Noci Darlene	Chief Development Officer	Aug 25 '25	Sale	74.62	4,000	298,489	48,034	Aug 27 04:30 PM
Porter James Richard	President and CEO	Aug 15 '25	Option Exercise	18.93	27,000	511,110	276,062	Aug 19 04:30 PM
Porter James Richard	President and CEO	Aug 15 '25	Sale	75.42	27,000	2,036,325	249,062	Aug 19 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Aug 07 '25	Option Exercise	27.71	5,500	152,415	66,456	Aug 08 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Aug 07 '25	Sale	74.85	5,500	411,675	60,956	Aug 08 04:30 PM
Noci Darlene	Chief Development Officer	Jul 30 '25	Option Exercise	27.85	4,000	111,400	52,034	Aug 01 04:30 PM
Noci Darlene	Chief Development Officer	Jul 30 '25	Sale	80.36	4,000	321,440	48,034	Aug 01 04:30 PM
BCLS II INVESTCO, LP	Former Affiliate	Jul 24 '25	Proposed Sale	82.08	4,253	349,086		Jul 24 08:42 PM
BCIP Life Sciences Associates,	Former Affiliate	Jul 24 '25	Proposed Sale	82.08	156,670	12,859,474		Jul 24 08:35 PM
Bain Capital Life Sciences Fun	Former Affiliate	Jul 24 '25	Proposed Sale	82.08	1,286,344	105,583,116		Jul 24 08:31 PM
Balcom Alexandra	Chief Financial Officer	Jul 16 '25	Option Exercise	18.93	14,700	278,271	76,434	Jul 17 04:32 PM
Balcom Alexandra	Chief Financial Officer	Jul 15 '25	Option Exercise	18.93	5,300	100,329	67,034	Jul 17 04:32 PM
Balcom Alexandra	Chief Financial Officer	Jul 16 '25	Sale	85.10	14,700	1,250,970	61,734	Jul 17 04:32 PM
Balcom Alexandra	Chief Financial Officer	Jul 15 '25	Sale	83.50	5,300	442,526	61,734	Jul 17 04:32 PM
Porter James Richard	President and CEO	Jul 15 '25	Option Exercise	18.93	27,000	511,110	276,062	Jul 17 04:31 PM
Porter James Richard	President and CEO	Jul 15 '25	Sale	82.27	27,000	2,221,419	249,062	Jul 17 04:31 PM
James Richard Porter	Officer	Jul 15 '25	Proposed Sale	84.59	81,000	6,851,790		Jul 15 04:01 PM
Pelish Henry E.	Chief Scientific Officer	Jul 10 '25	Option Exercise	28.75	5,500	158,123	66,456	Jul 11 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Jul 10 '25	Sale	79.98	5,500	439,905	60,956	Jul 11 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Jul 09 '25	Sale	81.16	2,145	174,081	60,956	Jul 11 04:30 PM
Henry E. Pelish	Officer	Jul 09 '25	Proposed Sale	81.15	2,145	174,076		Jul 09 06:06 PM
Balcom Alexandra	Chief Financial Officer	Jun 27 '25	Option Exercise	18.93	20,000	378,600	81,734	Jul 01 04:30 PM
Balcom Alexandra	Chief Financial Officer	Jun 27 '25	Sale	80.02	20,000	1,600,400	61,734	Jul 01 04:30 PM
Noci Darlene	Chief Development Officer	Jun 26 '25	Option Exercise	27.85	4,000	111,400	52,034	Jun 27 05:07 PM
Noci Darlene	Chief Development Officer	Jun 26 '25	Sale	78.71	4,000	314,826	48,034	Jun 27 05:07 PM
Pelish Henry E.	Chief Scientific Officer	Jun 25 '25	Option Exercise	28.70	8,630	247,676	71,731	Jun 27 05:05 PM
Pelish Henry E.	Chief Scientific Officer	Jun 27 '25	Option Exercise	29.09	2,170	63,133	65,271	Jun 27 05:05 PM
Pelish Henry E.	Chief Scientific Officer	Jun 25 '25	Sale	79.87	8,630	689,278	63,101	Jun 27 05:05 PM
Pelish Henry E.	Chief Scientific Officer	Jun 27 '25	Sale	79.92	2,170	173,426	63,101	Jun 27 05:05 PM
Alexandra Balcom	Officer	Jun 27 '25	Proposed Sale	80.00	129,480	10,358,400		Jun 27 04:18 PM
Darlene Noci	Officer	Jun 26 '25	Proposed Sale	79.07	12,000	948,840		Jun 26 04:03 PM
Porter James Richard	President and CEO	Jun 16 '25	Option Exercise	27.85	27,000	751,950	276,062	Jun 17 04:31 PM
Porter James Richard	President and CEO	Jun 16 '25	Sale	76.93	27,000	2,077,093	249,062	Jun 17 04:31 PM
Pelish Henry E.	Chief Scientific Officer	Jun 06 '25	Option Exercise	28.59	200	5,718	63,301	Jun 10 04:38 PM
Pelish Henry E.	Chief Scientific Officer	Jun 06 '25	Sale	79.82	200	15,964	63,101	Jun 10 04:38 PM
HENRY E PELISH	Officer	Jun 06 '25	Proposed Sale	78.09	22,000	1,717,980		Jun 06 04:24 PM
Noci Darlene	Chief Development Officer	May 29 '25	Option Exercise	20.69	4,000	82,765	52,034	May 30 04:31 PM
Noci Darlene	Chief Development Officer	May 29 '25	Sale	71.31	4,000	285,236	48,034	May 30 04:31 PM
Porter James Richard	President and CEO	May 15 '25	Option Exercise	27.85	27,000	751,950	276,062	May 16 04:30 PM
Porter James Richard	President and CEO	May 15 '25	Sale	69.60	27,000	1,879,216	249,062	May 16 04:30 PM
Noci Darlene	Chief Development Officer	Apr 29 '25	Option Exercise	14.40	4,000	57,600	52,034	May 01 04:45 PM
Noci Darlene	Chief Development Officer	Apr 29 '25	Sale	74.56	4,000	298,240	48,034	May 01 04:45 PM
Porter James Richard	President and CEO	Apr 15 '25	Option Exercise	27.85	27,000	751,950	276,062	Apr 17 04:55 PM
Porter James Richard	President and CEO	Apr 15 '25	Sale	68.94	27,000	1,861,504	249,062	Apr 17 04:55 PM
James Richard Porter	Officer	Apr 15 '25	Proposed Sale	70.00	81,000	5,670,000		Apr 15 04:15 PM
Noci Darlene	Chief Development Officer	Mar 27 '25	Option Exercise	16.92	4,000	67,688	52,034	Mar 28 04:45 PM
Noci Darlene	Chief Development Officer	Mar 27 '25	Sale	73.12	4,000	292,468	48,034	Mar 28 04:45 PM
Porter James Richard	President and CEO	Mar 17 '25	Option Exercise	27.85	27,000	751,950	276,062	Mar 19 04:47 PM
Porter James Richard	President and CEO	Mar 17 '25	Sale	75.87	27,000	2,048,562	249,062	Mar 19 04:47 PM
Noci Darlene	Chief Development Officer	Mar 06 '25	Option Exercise	2.63	30,000	78,967	78,034	Mar 10 04:48 PM
Noci Darlene	Chief Development Officer	Mar 07 '25	Option Exercise	1.08	4,000	4,320	52,034	Mar 10 04:48 PM
Noci Darlene	Chief Development Officer	Mar 06 '25	Sale	71.86	30,000	2,155,857	48,034	Mar 10 04:48 PM
Noci Darlene	Chief Development Officer	Mar 07 '25	Sale	71.93	4,000	287,721	48,034	Mar 10 04:48 PM
Darlene Noci	Officer	Mar 06 '25	Proposed Sale	76.67	46,000	3,526,800		Mar 06 04:03 PM
Shair Matthew	Director	Feb 24 '25	Sale	78.43	2,000	156,864	216,522	Feb 25 04:49 PM
Porter James Richard	President and CEO	Feb 18 '25	Option Exercise	27.85	27,000	751,950	276,062	Feb 20 04:57 PM
Porter James Richard	President and CEO	Feb 18 '25	Sale	78.46	27,000	2,118,336	249,062	Feb 20 04:57 PM
Pelish Henry E.	Chief Scientific Officer	Jan 31 '25	Option Exercise	0.87	3,120	2,714	63,101	Feb 04 04:46 PM
Shair Matthew	Director	Jan 27 '25	Sale	82.79	2,000	165,576	218,522	Jan 29 04:45 PM
Porter James Richard	President and CEO	Jan 15 '25	Option Exercise	27.85	27,000	751,950	276,062	Jan 17 04:43 PM
Porter James Richard	President and CEO	Jan 15 '25	Sale	75.99	27,000	2,051,777	249,062	Jan 17 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NUVL

Nuvalent Inc

Upgrade your FINVIZ experience